

Supplementary Table 1

Characteristics of RCT and non-RCT cohort

	RCT cohort (n=136)	Non-RCT cohort (n=160)	p value
Background characteristics			
Age: mean \pm SD	59.0 \pm 12.5	61.3 \pm 13.4	0.133
Man: n (%)	41 (30.1)	45 (28.1)	0.800
Previous SAH: n (%)	9 (6.6)	20 (12.5)	0.134
Previous hemorrhagic stroke: n (%)	1 (0.7)	8 (5.0)	0.073
Previous ischemic stroke: n (%)	3 (2.2)	16 (10.0)	0.013
Risk Factors: n (%)			
Hypertension	60 (44.1)	81 (50.6)	0.317
Diabetes	8 (5.9)	8 (5.0)	0.939
Dyslipidemia	45 (33.1)	52 (32.5)	1.000
Smoking habit	25 (18.4)	18 (11.2)	0.116
Target aneurysm, maximum diameter (mm): mean \pm SD	7.02 \pm 2.62	8.61 \pm 4.72	0.001
Radiographic outcome: n (%)			
Complete occlusion	49 (36.0)	59 (36.9)	
Neck remnant	49 (36.0)	48 (30.0)	
Aneurysm filling	38 (27.9)	53 (33.1)	
Initial combination of antiplatelet drugs: n (%)			
ASA+ CLP	134 (98.5)	120 (75.0)	0.108
ASA+CLP+CLZ	2 (1.5)	22 (13.8)	
ASA+CLP+PRG	0 (0.0)	3 (1.9)	
ASA+PRG	0 (0.0)	11 (6.9)	
CLP+CLZ	0 (0.0)	1 (0.6)	
ASA only	0 (0.0)	3 (1.9)	

Abbreviations: RCT, randomized control trial; SD, standard deviation; SAH, subarachnoid hemorrhage; ASA, acetylsalicylic acid (aspirin); CLP, clopidogrel; CLZ, cilostazol; PRG, prasugrel

Supplementary Table 2

Continued antiplatelet drug in reducing from DAPT to SAPT

	Long term DAPT (n=191)	Short term DAPT (n=105)	P value
Patient reducing to SAPT: n (%)	161 (84.3)	104 (99.0)	<0.001
Antiplatelet drugs after reducing to SAPT: n (%)			0.340
Aspirin	81 (50.3)	58 (55.8)	
Clopidogrel	63 (39.1)	41 (39.4)	
Cilostazol	15 (9.3)	5 (4.8)	
Prasugrel	2 (1.2)	0 (0.0)	

Abbreviations: DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy

Supplementary Table 3

Platelet aggregation study (Verify Now™) at registration and 6 and 12 months after SACE

	Long term DAPT (n=191)				Short term DAPT (n=105)			
	n	Median	Q1	Q3	n	Median	Q1	Q3
ARU								
Registration	243	435.0	403.0	506.0	148	429.0	397.0	505.0
6 months	100	456.0	396.5	513.5	60	502.0	431.0	612.0
12 months	83	430.0	400.0	525.0	55	516.0	421.0	618.0
PRU								
Registration	244	178.0	121.0	218.0	152	177.5	129.0	225.0
6 months	100	165.5	119.5	202.0	59	221.0	171.0	260.0
12 months	84	171.5	125.0	235.0	57	211.0	166.0	257.0

Abbreviations: SACE, stent assisted coil embolization; DAPT, dual antiplatelet therapy; ARU, aspirin reaction units; PRU, P2Y12 reaction units

Supplementary Table 4

Relation between timing from DAPT to SAPT and events

Ischemic stroke

Event number	Group	Duration from SACE to event (days)	Situation of antiplatelet therapy at event	Duration from starting of SAPT to event (days)
1	long term DAPT	11	DAPT	NA
2	long term DAPT	24	DAPT	NA
3	long term DAPT	216	SAPT	13
4	long term DAPT	371	DAPT	NA
5	long term DAPT	391	DAPT	NA
6	long term DAPT	394	SAPT	28
7	short term DAPT	6	DAPT	NA
8	short term DAPT	10	SAPT	10
9	short term DAPT	20	DAPT	NA
10	short term DAPT	97	SAPT	9

Hemorrhagic event

Event number	Group	Duration from SACE to event (days)	Situation of antiplatelet therapy at event	Duration from event to starting SAPT (days)
1	long term DAPT	184	DAPT	NA
2	long term DAPT	374	DAPT	1
3	short term DAPT	35	SAPT	NA
4	short term DAPT	40	DAPT	2
5	short term DAPT	60	DAPT	2
6	short term DAPT	230	SAPT	NA

Abbreviations: SACE, stent-assisted coil embolization; DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; NA, not applicable